Correlation Between Pfizer and NOVARTIS
Specify exactly 2 symbols:
By analyzing existing cross correlation between Pfizer Inc and NOVARTIS CAPITAL P, you can compare the effects of market volatilities on Pfizer and NOVARTIS and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pfizer with a short position of NOVARTIS. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pfizer and NOVARTIS.
Diversification Opportunities for Pfizer and NOVARTIS
Modest diversification
The 3 months correlation between Pfizer and NOVARTIS is 0.24. Overlapping area represents the amount of risk that can be diversified away by holding Pfizer Inc and NOVARTIS CAPITAL P in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NOVARTIS CAPITAL P and Pfizer is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pfizer Inc are associated (or correlated) with NOVARTIS. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NOVARTIS CAPITAL P has no effect on the direction of Pfizer i.e., Pfizer and NOVARTIS go up and down completely randomly.
Pair Corralation between Pfizer and NOVARTIS
Considering the 90-day investment horizon Pfizer Inc is expected to generate 1.93 times more return on investment than NOVARTIS. However, Pfizer is 1.93 times more volatile than NOVARTIS CAPITAL P. It trades about 0.19 of its potential returns per unit of risk. NOVARTIS CAPITAL P is currently generating about -0.21 per unit of risk. If you would invest 2,486 in Pfizer Inc on September 18, 2024 and sell it today you would earn a total of 156.50 from holding Pfizer Inc or generate 6.3% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 95.24% |
| Values | Daily Returns |
Pfizer Inc vs. NOVARTIS CAPITAL P
Performance |
| Timeline |
| Pfizer Inc |
| NOVARTIS CAPITAL P |
Pfizer and NOVARTIS Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Pfizer and NOVARTIS
The main advantage of trading using opposite Pfizer and NOVARTIS positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pfizer position performs unexpectedly, NOVARTIS can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NOVARTIS will offset losses from the drop in NOVARTIS's long position.| Pfizer vs. Emergent Biosolutions | Pfizer vs. Neurocrine Biosciences | Pfizer vs. Teva Pharma Industries | Pfizer vs. Haleon plc |
| NOVARTIS vs. Universal Music Group | NOVARTIS vs. Canlan Ice Sports | NOVARTIS vs. Microbot Medical | NOVARTIS vs. Mills Music Trust |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Complementary Tools
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |